| VTVT:vTv Therapeutics Inc | | Charting | News | Options | |||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
0.00% $0.00
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT |
|
| PR Newswire |
|
Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly diagnosed glioblastoma |
| Full Story → |
|
| Headline News |
|
| vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update |
| 8:00a ET March 13 '24 GlobeNewswire |
|
|
| vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes |
| 8:00a ET March 4 '24 GlobeNewswire |
|
|
| vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference |
| 8:00a ET March 1 '24 GlobeNewswire |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| April 24 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 24 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
3.07%
14.20% 
